Filing Flows › Orchestra BioMed Holdings (OBIO) › Q2 2026 › vs Q2 2025
Orchestra BioMed Holdings (OBIO) Q2 2026 vs Q2 2025 (year over year)
Orchestra BioMed Holdings's revenue fell $748K (-89%) from $836K in Q2 2025 to $88K in Q2 2026.
Orchestra BioMed Holdings, Q2 2026: revenue $88K (-90% year over year), net loss $23.8M, operating cash flow −$19.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $88K | $836K | −$748K | -89% |
| Net loss | $23.8M | $19.4M | $4.4M | +23% |
| Costs & expenses | $23.8M | $20.2M | $3.6M | +18% |
| Operating costs | $22.4M | $20.2M | $2.3M | +11% |
| Interest & other, net | $1.4M | $36K | $1.4M | 39× |
| Cost of revenue | $25K | $46K | −$21K | -46% |
| Research & development | $16.6M | $13.9M | $2.7M | +20% |
| SG&A | $5.8M | $6.3M | −$435K | -7% |
| Operating cash sources | $23.8M | $19.4M | $4.4M | +23% |
| Depreciation & amortization | $96K | $81K | $15K | +19% |
| Share-based compensation | $2.5M | $3.2M | −$745K | -23% |
| Working capital & other | $1.8M | $505K | $1.3M | +261% |
| Cash used in operations | $19.3M | $15.5M | $3.8M | +25% |
| Net loss absorbed | $23.8M | $19.4M | $4.4M | +23% |
Questions
How much did Orchestra BioMed Holdings's revenue grow year over year in Q2 2026?
Orchestra BioMed Holdings's revenue fell $748K (-89%) from $836K in Q2 2025 to $88K in Q2 2026.